BMS-927711: A Potent CGRP Receptor Antagonist for Migraine Treatment
Discover the advanced pharmaceutical intermediate BMS-927711, a selective CGRP receptor antagonist developed for the acute treatment of migraines. As a leading manufacturer and supplier in China, NINGBO INNO PHARMCHEM CO.,LTD. offers this high-purity compound to support your research and development needs.
Get a Quote & SampleUnlock Novel Migraine Therapies with BMS-927711
BMS-927711
NINGBO INNO PHARMCHEM CO.,LTD. is a trusted supplier of BMS-927711 (CAS 1289023-67-1), a highly selective and orally bioavailable antagonist targeting the calcitonin gene-related peptide (CGRP) receptor. This critical pharmaceutical intermediate plays a vital role in developing advanced treatments for conditions like migraine, offering a distinct advantage over traditional therapies by minimizing cardiovascular risks. Secure your supply from a reliable manufacturer in China.
- Potent CGRP Receptor Antagonism: BMS-927711 exhibits potent antagonism, crucial for developing effective migraine treatments.
- Orally Bioavailable: Designed for oral administration, enhancing patient convenience and compliance for migraine sufferers.
- Minimizes Cardiovascular Risk: Unlike triptans, this CGRP antagonist counteracts vasodilation without causing non-selective vasoconstriction, a key safety advantage.
- Supports Migraine Pathogenesis Research: Ideal for R&D in neuroscience and pharmaceutical sectors investigating CGRP's role in migraines.
Advantages of Sourcing BMS-927711 from NINGBO INNO PHARMCHEM
Uncompromising Quality and Purity
As a leading manufacturer, we ensure the highest purity and quality for BMS-927711, critical for pharmaceutical research and development. Rely on our consistent supply chain for your demanding projects.
Cost-Effective Sourcing in China
We offer competitive pricing for BMS-927711, making it an economically viable option for your procurement needs. Purchase high-grade pharmaceutical intermediates directly from a trusted Chinese supplier.
Expert Technical Support
Leverage our expertise in pharmaceutical intermediates. We provide comprehensive technical data and support to assist you in integrating BMS-927711 into your formulations and research protocols.
Key Application Areas for BMS-927711
Migraine Treatment Development
BMS-927711 is a crucial component in the research and development of novel oral treatments for migraine, addressing a significant unmet medical need.
Neuroscience Research
Its specific action on the CGRP receptor makes it an invaluable tool for scientists studying the role of CGRP in neurological pathways and pain management.
Pharmaceutical Intermediate Supply
As a high-quality pharmaceutical intermediate, it supports the synthesis of active pharmaceutical ingredients (APIs) in drug manufacturing.
Clinical Trials Support
Reliable sourcing of BMS-927711 is essential for companies conducting Phase II clinical trials for migraine therapies.